The US Food and Drug Administration (FDA) have approved three generic versions of Roche’s osteoporosis medication Boniva.
Copies of the once-monthly, 150mg tablets, produced by Mylan, Apotex and Orchid Chemicals & Pharmaceuticals, can now be marketed towards sufferers of the bone condition.
Go deeper with GlobalData
US FDA Centre for Drug Evaluation and Research Office of Pharmaceutical Science deputy director Keith Webber heralded the arrival of generic treatments for the disease.
“For people who must manage their health conditions over time, it is important to have affordable treatment options,” added Webber.
Osteoporosis is the most common type of bone disease, affecting more than 40 million people in the US, and leads to bone fragility and an increased risk of bone fractures due to low bone mass and bone tissue deterioration.
Boniva, belonging to the bisphosphonate class of drugs, directly competes with other bisphosphonates including Novartis’ Reclast/Aclasta/Zometa and Merck & Co’s Fosamax for a target group estimated to be around 5 million people in the US alone.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSales of Boniva are now widely predicted to take a further fall, following on from a 31.3% decrease recorded in 2011.
